Investment Thesis
Instil Bio is a pre-revenue biotech company facing critical liquidity crisis with only ~2.2 months of cash runway ($6.6M cash against -$36.6M annual burn). Zero revenue combined with -$78.6M operating losses indicates failed or stalled product development with no near-term commercialization path. Without immediate capital raise or dramatic expense reduction, the company faces existential risk.
Strengths
- Zero debt burden (Debt/Equity 0.00x) eliminates bankruptcy risk from creditors
- Asset base of $203.5M provides some tangible value, though immediate liquidity is critical
- Operating loss improved 3.7% YoY, suggesting cost controls or restructuring efforts
Risks
- Critical cash runway of approximately 2.2 months at current burn rate poses imminent solvency risk
- Zero revenue with no disclosed path to commercialization; suggests failed candidates or extremely early stage development
- Severe value destruction evidenced by ROE of -62.7% and ROA of -35.1% signals unsustainable business model
- Massive operating losses (-$78.6M) on zero revenue indicate fundamental business challenges beyond typical biotech risk
- Dilutive capital raise likely imminent, threatening shareholder equity
Key Metrics to Watch
- Cash balance and monthly burn rate (critical for survival timeline)
- Capital raise announcements and terms (equity dilution risk)
- Clinical/regulatory progress on product candidates and potential revenue catalysts
- Operating expense trends and path to sustainability
Financial Metrics
Revenue
0.0
Net Income
-71.4M
EPS (Diluted)
$-10.70
Free Cash Flow
-36.6M
Total Assets
203.5M
Cash
6.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-62.7%
ROA
-35.1%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
39.53x
Quick Ratio
39.53x
Debt/Equity
0.00x
Debt/Assets
44.1%
Interest Coverage
-39.67x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-17T11:18:26.834380 |
Data as of: 2025-12-31 |
Powered by Claude AI